Suggestions
Jason Black
General Partner at RRE Ventures and active investor
Jason Black is an investor at Kindo, a position he has held since July 2023. He is based in New York and has extensive experience in the venture capital sector. Prior to his role at Kindo, Black worked at RRE Ventures, where he has held multiple positions since 2014, including General Partner and Principal. He is also involved with several companies as a board member or observer, including Summer, OpenEnvoy, and Boost, among others.
Black's educational background includes attending Harvard University, where he was the founder and editor-in-chief of the Harvard College Tech Review. His early career included roles at Microsoft, where he contributed to product planning and design research.1
Highlights
(1/2) Random Rabbit Hole 🕳️ : OVT & Medical Self-Experimentation
My initial kick down this rabbit hole was Beate Halassy's treatment of her own breast cancer.
As a virologist herself, she used a method of oncolytic virotherapy (OVT) to successfully treat her own breast cancer. There are no FDA approved OVTs to treat breast cancer on the market (+60 clinical trials)—mind blowing that there are no approved therapies, given that the underlying OVT mechanism was first discovered in the 1950's.
There have been a lot of great breakdowns of her treatment path, including this tweet thread / Nature article by @NTFabiano here: https://t.co/Vrueq0YJzK
I don't disagree in principle, but the reality of many of these "straightforward" workflows are rarely as straightforward as they outwardly appear.
Counter-positioned AI business should expect to spend a tremendous amount of time solving the long-tail.
This point visualized: https://t.co/f7FpT42NUB
